Few Biomarkers and Targeted Anti-cancer Treatment
|PD L1||Pembrolizumab||Bladder, Breast, Cervical, Lung, |
Vulvar, Head and neck cancers
|ER / PR||Megestrol acetate||Breast, Uterine cancers,
|HER2 / |
|Trastuzumab||Breast, Colorectal, Gastric,
Esophageal, Uterine cancers
Pinaka™ is an advanced non-invasive blood test which provides therapeutically relevant information via a safe, simple and quick blood draw. Pinaka™ evaluates blood sample to detect ‘Circulating Tumor Cells’ (CTCs), which are cancer cells that escape from the tumor and enter the blood stream. Pinaka™ enriches these CTCs from the blood sample and confirms their identity via a process called ‘Immunocytochemistry’ (ICC). Pinaka also determines the status of the above biomarkers on CTCs either via ICC or by fluorescent in situ hybridization (FISH).
The technology of Pinaka™ is based on the ubiquity of CTCs and the highly efficient CTC detection process. This technology has a low false negative rate (high ‘sensitivity’) as well as a low false positive rate (high ‘specificity’). These factors translate into a safe blood test for accurate and reliable determination of the status of the above biomarkers.
Turn Around Time
Typically, we are able to complete the test and analysis in 08 days and issue the final report within 10 days of the receipt of the sample at our facility.
Cancer and Biomarker Coverage
|Cancer Type||PD L1*||ER*||PR*||HER2**||EGFR**|
|Central Nervous System||-||-||-||-||-|
|Head and Neck||✓||-||-||-||-|
Pinaka™can provide accurate and reliable determination of the status of the above biomarkers, which can assist physicians to make life-saving treatment and clinical management decisions more effectively.